Eric L. Haseltine

Rapid in silico directed evolution by a protein language model with EVOLVEpro

Future therapies for cystic fibrosis

A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation

Synthetic Gene Circuits: Design with Directed Evolution